Lirilumab ELISA Kit
Product Specifications
Background
Lirilumab (IPH2102/BMS-986015/BMS-986015-01) is a fully human monoclonal antibody (mAb) that is designed to block the interaction between KIR2DL-1, -2, -3 inhibitory receptors and their ligands. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb. A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017. It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned. On 22 May 2018, a clinical trial for Bladder Cancer was started by PrECOG LLC.
Specifications
Lirilumab
Product Name Alternative
BMS-986015, IPH2102, CAS: 1000676-41-4
Detection Method
Colorimetric
Assay Type
Quantitative
Sample Type
Plasma, Serum
Detection Range
0.31-5 μg/mL
Recovery
80-120%
Sensitivity
0.156 μg/ml
Shipping Conditions
2-8 °C
Storage Conditions
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Notes
For Research Use Only.
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6470122-01 0.2 mL
Connexin 36, CT (GJA9, Gap Junction delta-2 Protein, Gap Junction alpha-9 Protein, Connexin-36, Cx36, GJD2) (PE)
Sign In for Pricing
View Details 
MBS6470122-02 5x 0.2 mL
Connexin 36, CT (GJA9, Gap Junction delta-2 Protein, Gap Junction alpha-9 Protein, Connexin-36, Cx36, GJD2) (PE)
Sign In for Pricing
View Details 